Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mecapegfilgrastim + Adebrelimab + FLOT in Resectable GC/GEJC
NCT06684158Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Nov 2024
- Primary completion
- Mar 2027
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mecapegfilgrastim in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Pathologic Complete Response at 12 weeks. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
mecapegfilgrastim
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06684158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06684158.